DarioHealth (NSDQ:DRIO) said today that it inked a deal with an unnamed pharmaceutical company to combine its blood glucose monitoring tech into the company’s clinical trial.
The Israel-based device-maker reported that this pharmaceutical company is conducting a trial of its diabetes drug that will eventually be included in a regulatory package for FDA approval.
Get the full story at our sister site, Drug Delivery Business News.